Page last updated: 2024-10-30

metformin and Liver Diseases

metformin has been researched along with Liver Diseases in 32 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Liver Diseases: Pathological processes of the LIVER.

Research Excerpts

ExcerptRelevanceReference
"Metformin inhibits cyclic AMP generation and activates AMP-activated protein kinase (AMPK), which inhibits the cystic fibrosis transmembrane conductance regulator and Mammalian Target of Rapamycin pathways."9.27A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. ( Abebe, KZ; Bae, KT; Hallows, KR; Miskulin, DC; Perrone, RD; Seliger, SL; Watnick, T, 2018)
"Our findings suggest that metformin might reduce the rates or severity of liver dysfunction in selected high-risk adolescents."9.12Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. ( Freemark, M, 2007)
"To synthesize data addressing outcomes of metformin use in populations with type 2 diabetes and moderate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment."8.95Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. ( Cameron, CB; Crowley, MJ; Diamantidis, CJ; Kosinski, AS; McDuffie, JR; Mock, CK; Nagi, A; Stanifer, JW; Tang, S; Wang, X; Williams, JW, 2017)
"We assessed racial/ethnic disparity in hepatocellular carcinoma (HCC) incidence among men with type 2 diabetes (T2D) but without chronic liver diseases (CLD), and whether metformin use modified the disparity."7.91Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases. ( Kuhn, J; Lam, YF; MacCarthy, D; Ramirez, AG; Schmidt, S; Shah, DP; Tenner, L; Wang, CP, 2019)
"To estimate the incidence of lactic acidosis (LA) and role of metformin in Japanese patients with type 2 diabetes mellitus (T2DM) treated with anti-diabetes drugs."7.83Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan. ( Chang, CH; Dolin, P; Sakaguchi, M, 2016)
"In 84% of the cases, type 2 diabetes mellitus has been present before the HCC diagnosis."5.36Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. ( Balbi, M; Casarin, P; Donadon, V; Mas, MD; Zanette, G, 2010)
"GVHD had little effect."5.35O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009)
"Metformin inhibits cyclic AMP generation and activates AMP-activated protein kinase (AMPK), which inhibits the cystic fibrosis transmembrane conductance regulator and Mammalian Target of Rapamycin pathways."5.27A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. ( Abebe, KZ; Bae, KT; Hallows, KR; Miskulin, DC; Perrone, RD; Seliger, SL; Watnick, T, 2018)
"Our findings suggest that metformin might reduce the rates or severity of liver dysfunction in selected high-risk adolescents."5.12Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. ( Freemark, M, 2007)
"To synthesize data addressing outcomes of metformin use in populations with type 2 diabetes and moderate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment."4.95Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. ( Cameron, CB; Crowley, MJ; Diamantidis, CJ; Kosinski, AS; McDuffie, JR; Mock, CK; Nagi, A; Stanifer, JW; Tang, S; Wang, X; Williams, JW, 2017)
"The FDA approved 'label' for metformin lists hepatic insufficiency as a risk for lactic acidosis."3.96The safety and pharmacokinetics of metformin in patients with chronic liver disease. ( Braithwaite, HE; Carland, JE; Cheng, TS; Danta, M; Day, RO; Graham, GG; Greenfield, JR; Kumar, SS; Liu, Z; Smith, FC; Stocker, SL; Williams, KM, 2020)
"We assessed racial/ethnic disparity in hepatocellular carcinoma (HCC) incidence among men with type 2 diabetes (T2D) but without chronic liver diseases (CLD), and whether metformin use modified the disparity."3.91Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases. ( Kuhn, J; Lam, YF; MacCarthy, D; Ramirez, AG; Schmidt, S; Shah, DP; Tenner, L; Wang, CP, 2019)
"To estimate the incidence of lactic acidosis (LA) and role of metformin in Japanese patients with type 2 diabetes mellitus (T2DM) treated with anti-diabetes drugs."3.83Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan. ( Chang, CH; Dolin, P; Sakaguchi, M, 2016)
"Treatment with metformin is occasionally associated with the development of severe lactic acidosis."3.69Contraindications to metformin therapy in patients with NIDDM. ( Bosman, D; Krentz, AJ; Sulkin, TV, 1997)
"Metformin treatment showed either small mean increases or decreases."2.71Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. ( Belcher, G; Schernthaner, G, 2005)
"Patients with type 2 diabetes have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis and about one-third of cirrhotic patients have diabetes."2.50Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. ( Scheen, AJ, 2014)
"Physiologically based pharmacokinetic (PBPK) modelling and simulation enable researchers to overcome practical limitations for clinical trials on special populations."1.46Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations. ( Chung, H; Chung, JY; Rhee, SJ; Yi, S; Yu, KS, 2017)
"Metformin is an antidiabetic agent that decreases hyperglycemia by different pathways than insulin; therefore, we asked whether metformin affects postburn ER stress and hepatic metabolism."1.39Effects of metformin on burn-induced hepatic endoplasmic reticulum stress in male rats. ( Arno, A; Herndon, DN; Hiyama, Y; Jeschke, MG; Kraft, R; Marshall, AH; Qa'aty, N, 2013)
"In 84% of the cases, type 2 diabetes mellitus has been present before the HCC diagnosis."1.36Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. ( Balbi, M; Casarin, P; Donadon, V; Mas, MD; Zanette, G, 2010)
"GVHD had little effect."1.35O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009)

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19903 (9.38)18.7374
1990's1 (3.13)18.2507
2000's6 (18.75)29.6817
2010's15 (46.88)24.3611
2020's7 (21.88)2.80

Authors

AuthorsStudies
Dare, A1
Channa, ML1
Nadar, A1
Song, H3
Zhang, X5
Zhai, R1
Liang, H1
Song, G1
Yuan, Y1
Xu, Y2
Yan, Y1
Qiu, L1
Sun, T1
Ajiboye, BO1
Dada, S1
Fatoba, HO1
Lawal, OE1
Oyeniran, OH1
Adetuyi, OY1
Olatunde, A1
Taher, M1
Khotib, J1
Susanti, D1
Oyinloye, BE1
Smith, FC1
Stocker, SL1
Danta, M1
Carland, JE1
Kumar, SS1
Liu, Z3
Greenfield, JR1
Braithwaite, HE1
Cheng, TS1
Graham, GG1
Williams, KM1
Day, RO1
Bao, S1
Wu, YL1
Wang, X7
Han, S1
Cho, S1
Ao, W1
Nan, JX1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J2
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S2
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y5
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H2
Yang, T2
Dong, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Sato, Y2
Hirose, T1
Miura, T1
Kohzuki, M1
Ito, O1
Rhee, SJ1
Chung, H1
Yi, S1
Yu, KS1
Chung, JY1
Dawson, AJ1
Kilpatrick, ES1
Coady, AM1
Elshewehy, AMM1
Dakroury, Y1
Ahmed, L1
Atkin, SL1
Sathyapalan, T1
Seliger, SL1
Abebe, KZ1
Hallows, KR1
Miskulin, DC1
Perrone, RD1
Watnick, T1
Bae, KT1
Mansourian, M1
Sadeghi, H1
Doustimotlagh, AH1
Iranshahy, M1
Rezaee, R1
Karimi, G1
Abruzzese, GA1
Heber, MF1
Ferrer, MJ1
Ferreira, SR1
Silva, AF1
Motta, AB1
Wang, CP1
Kuhn, J1
Shah, DP1
Schmidt, S1
Lam, YF1
MacCarthy, D1
Tenner, L1
Ramirez, AG1
Scheen, AJ1
Ruiz-Tamayo, I1
Franch-Nadal, J1
Mata-Cases, M1
Mauricio, D1
Cos, X1
Rodriguez-Poncelas, A1
Barrot, J1
Coll-de-Tuero, G1
Mundet-Tudurí, X1
Chang, CH1
Sakaguchi, M1
Dolin, P1
Umpaichitra, V1
Crowley, MJ1
Diamantidis, CJ1
McDuffie, JR1
Cameron, CB1
Stanifer, JW1
Mock, CK1
Nagi, A1
Kosinski, AS1
Williams, JW1
Harvey, SB1
Wilson-Grady, J1
Monkkonen, T1
Nelsestuen, GL1
Kasthuri, RS1
Verneris, MR1
Lund, TC1
Ely, EW1
Bernard, GR1
Zeisler, H1
Homoncik, M1
Jilma, B1
Swan, T1
Kellogg, TA1
Vuppalanchi, R1
Chalasani, N1
Wei, J1
Xue, R1
Wu, JD1
Zhao, W1
Wang, ZZ1
Wang, SK1
Zhou, ZX1
Song, DQ1
Wang, YM1
Pan, HN1
Kong, WJ1
Jiang, JD1
Donadon, V1
Balbi, M1
Mas, MD1
Casarin, P1
Zanette, G1
Hiyama, Y1
Marshall, AH1
Kraft, R1
Qa'aty, N1
Arno, A1
Herndon, DN1
Jeschke, MG1
Edwards, CM1
Barton, MA1
Snook, J1
David, M1
Mak, VH1
Chowdhury, TA1
Belcher, G1
Schernthaner, G1
Freemark, M1
Sulkin, TV1
Bosman, D1
Krentz, AJ1
Emslie-Smith, AM1
Boyle, DI1
Evans, JM1
Sullivan, F1
Morris, AD1
Streda, M1
Sachs, BA1
Bardfeld, PA1
Bodian, JE1
Sugarman, LA1
Hellman, L1
Schneider, T1
Lopis, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571]1,080 participants (Anticipated)Observational2019-04-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for metformin and Liver Diseases

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Hepatoprotective activity of metformin: A new mission for an old drug?
    European journal of pharmacology, 2019, May-05, Volume: 850

    Topics: Animals; Cytoprotection; Humans; Liver; Liver Diseases; Metformin; Xenobiotics

2019
Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
    Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:6

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hepatic Insufficiency; Humans; Hypogl

2014
Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.
    Annals of internal medicine, 2017, Feb-07, Volume: 166, Issue:3

    Topics: Cause of Death; Chronic Disease; Contraindications; Diabetes Mellitus, Type 2; Heart Failure; Humans

2017
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1

    Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type

2009
Glucose tolerance tests in the clinical picture of chronic liver diseases.
    Acta Universitatis Carolinae. Medica. Monographia, 1975, Issue:67

    Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight

1975

Trials

8 trials available for metformin and Liver Diseases

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
    BMC endocrine disorders, 2017, Jul-14, Volume: 17, Issue:1

    Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-C

2017
A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
    American journal of nephrology, 2018, Volume: 47, Issue:5

    Topics: Adolescent; Adult; Clinical Trials, Phase II as Topic; Cysts; Disease Progression; Dose-Response Rel

2018
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
    Metabolism: clinical and experimental, 2010, Volume: 59, Issue:2

    Topics: Aged; Berberine; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Gene Expression; Human

2010
Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:8

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated He

2005
Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin.
    Acta paediatrica (Oslo, Norway : 1992), 2007, Volume: 96, Issue:9

    Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Colorimetry; Diabetes Mellitus, Type

2007
Liver scan in hyperlipoproteinemia.
    JAMA, 1974, Feb-25, Volume: 227, Issue:8

    Topics: Adult; Aged; Aspartate Aminotransferases; Blood Protein Disorders; Blood Protein Electrophoresis; Ch

1974
HB419 (glibenclamide) in the treatment of diabetes mellitus.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1969, Aug-09, Volume: 43, Issue:32

    Topics: Adult; Age Factors; Aged; Biguanides; Chlorpropamide; Clinical Trials as Topic; Diabetes Complicatio

1969

Other Studies

19 other studies available for metformin and Liver Diseases

ArticleYear
L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia.
    Canadian journal of physiology and pharmacology, 2021, Volume: 99, Issue:11

    Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combina

2021
Metformin attenuated sepsis-associated liver injury and inflammatory response in aged mice.
    Bioengineered, 2022, Volume: 13, Issue:2

    Topics: Aging; Animals; Inflammation; Lipopolysaccharides; Liver; Liver Diseases; Male; Metformin; Mice; Mic

2022
Dalbergiella welwitschia (Baker) Baker f. alkaloid-rich extracts attenuate liver damage in streptozotocin-induced diabetic rats.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 168

    Topics: Alkaloids; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Hypoglycemic Agents

2023
The safety and pharmacokinetics of metformin in patients with chronic liver disease.
    Alimentary pharmacology & therapeutics, 2020, Volume: 51, Issue:5

    Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Chronic Disease; Comorbidity; Cross-Sectional Stud

2020
Agriophyllum oligosaccharides ameliorate hepatic injury in type 2 diabetic db/db mice targeting INS-R/IRS-2/PI3K/AKT/PPAR-γ/Glut4 signal pathway.
    Journal of ethnopharmacology, 2020, Jul-15, Volume: 257

    Topics: Animals; Biomarkers; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Disease Models, A

2020
Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
    American journal of physiology. Gastrointestinal and liver physiology, 2021, 04-01, Volume: 320, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Cell Proliferation; Cysts; Disease Progression; Enzyme Activ

2021
Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
    European journal of drug metabolism and pharmacokinetics, 2017, Volume: 42, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Computer Simulation; Female; Humans; Kidney Diseases; L

2017
Activation of the Glutathione Peroxidase by Metformin in the Bile-duct Ligation induced Liver Injury: In vivo Combined with Molecular Docking Studies.
    Current pharmaceutical design, 2018, Volume: 24, Issue:27

    Topics: Animals; Bile Ducts; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione Peroxidas

2018
Effects of in utero androgen excess and metformin treatment on hepatic functions.
    Molecular and cellular endocrinology, 2019, 07-01, Volume: 491

    Topics: Animals; Female; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Dis

2019
Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases.
    Cancer medicine, 2019, Volume: 8, Issue:6

    Topics: Aged; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Healthcare Disparit

2019
Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Cross-Sectional Studies; Diabetes Complications; Diabet

2016
Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan.
    Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:10

    Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Ty

2016
Unusual glycogenic hepatopathy causing abnormal liver enzymes in a morbidly obese adolescent with well-controlled type 2 diabetes: resolved after A1c was normalized by metformin.
    Clinical obesity, 2016, Volume: 6, Issue:4

    Topics: Adolescent; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Liver Diseases; Male; Metformin;

2016
O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease.
    Journal of proteome research, 2009, Volume: 8, Issue:2

    Topics: Adult; Aged; Apolipoprotein C-III; Bariatric Surgery; Biomarkers; Diabetes Mellitus; Female; Glycosi

2009
Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:5

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Chronic Disease; Diabetes Mellitus, Ty

2010
Effects of metformin on burn-induced hepatic endoplasmic reticulum stress in male rats.
    Molecular medicine (Cambridge, Mass.), 2013, Mar-05, Volume: 19

    Topics: Alanine Transaminase; Albumins; Animals; Endoplasmic Reticulum Stress; Fatty Acids; Gene Expression

2013
Metformin-associated lactic acidosis in a patient with liver disease.
    QJM : monthly journal of the Association of Physicians, 2003, Volume: 96, Issue:4

    Topics: Acidosis, Lactic; Adult; Diabetes Mellitus, Type 2; Fatal Outcome; Humans; Hypoglycemic Agents; Live

2003
Contraindications to metformin therapy in patients with NIDDM.
    Diabetes care, 1997, Volume: 20, Issue:6

    Topics: Acidosis, Lactic; Alcoholism; Contraindications; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; D

1997
Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines.
    Diabetic medicine : a journal of the British Diabetic Association, 2001, Volume: 18, Issue:6

    Topics: Cohort Studies; Contraindications; Databases as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropat

2001